Bevacizumab Suppliers & Bulk Manufacturers
Available Forms: Injection
Available Strengths: 100 mg/4 mL, 400 mg/16 mL
Reference Brands: Avastin (USA)
Category:
Oncology Cancer Care
Bevacizumab is a recombinant humanized monoclonal antibody that targets vascular endothelial growth factor (VEGF), a protein responsible for the growth of new blood vessels. By blocking VEGF, it helps prevent the formation of blood vessels that feed tumors, thereby slowing their growth.
Bevacizumab is available in Injection
and strengths such as 100 mg/4 mL, 400 mg/16 mL.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Bevacizumab is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Bevacizumab can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Bevacizumab is a monoclonal antibody and anti-angiogenesis agent that works by binding to vascular endothelial growth factor (VEGF), helping to prevent the formation of new blood vessels that tumors need to grow. It is used to treat a variety of cancers, including cervical cancer, colorectal cancer, non-small cell lung cancer, renal cell carcinoma, glioblastoma, ovarian epithelial cancer, fallopian tube cancer, primary peritoneal cancer, and hepatocellular carcinoma.
Bevacizumab is available under multiple brand names, including Avastin®, Alymsys®, Mvasi®, and Zirabev®, and can be used alone or in combination with other anticancer therapies depending on the indication. By inhibiting tumor angiogenesis, bevacizumab slows cancer progression and helps improve treatment outcomes.
The drug is also under investigation for use in other cancer types, reflecting its broad potential as a targeted therapy. Administered as a sterile intravenous infusion, bevacizumab requires careful monitoring for adverse effects such as hypertension, bleeding, and impaired wound healing. Its targeted mechanism and multiple approved indications make it a cornerstone in modern oncology therapy.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing